| Literature DB >> 27754437 |
Laura Capelli1, Gianluigi Taverna2,3, Alessia Bellini4, Lidia Eusebio5, Niccolò Buffi6, Massimo Lazzeri7, Giorgio Guazzoni8, Giorgio Bozzini9, Mauro Seveso10, Alberto Mandressi11, Lorenzo Tidu12, Fabio Grizzi13, Paolo Sardella14, Giuseppe Latorre15, Rodolfo Hurle16, Giovanni Lughezzani17, Paolo Casale18, Sara Meregali19, Selena Sironi20.
Abstract
The electronic nose is able to provide useful information through the analysis of the volatile organic compounds in body fluids, such as exhaled breath, urine and blood. This paper focuses on the review of electronic nose studies and applications in the specific field of medical diagnostics based on the analysis of the gaseous headspace of human urine, in order to provide a broad overview of the state of the art and thus enhance future developments in this field. The research in this field is rather recent and still in progress, and there are several aspects that need to be investigated more into depth, not only to develop and improve specific electronic noses for different diseases, but also with the aim to discover and analyse the connections between specific diseases and the body fluids odour. Further research is needed to improve the results obtained up to now; the development of new sensors and data processing methods should lead to greater diagnostic accuracy thus making the electronic nose an effective tool for early detection of different kinds of diseases, ranging from infections to tumours or exposure to toxic agents.Entities:
Keywords: VOCs; biomarkers; olfaction; prostate cancer; urine analysis
Year: 2016 PMID: 27754437 PMCID: PMC5087496 DOI: 10.3390/s16101708
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Application of e-nose for evaluation of different diseases using urine samples.
| Reference Number | Authors (Year) | Disease Studied | Detection System | Data Processing Methods |
|---|---|---|---|---|
| [ | Pavlou et al. (2002) | BC | 14 CP | GA, NN, PCA, DFA-cv |
| [ | Bruins et al. (2009) | BC | 1 MOS | SW-MV, DTW |
| [ | Yates et al. (2005) | BC | 32 CP (Cyrano Sciences C320, Smiths Detection, Bushey, Hertfordshire, UK) | MPL, ARX, RBFs, non linear ARX |
| [ | Aathithan et al. (2001) | BC | 4 CP (Osmetech Microbial Analyzer-OMA, Osmetech plc, Crewe, UK) | PCA |
| [ | Pavlou et al. (2002) | UTI | 14 CP | GA, NN, PCA, DFA-cv |
| [ | Kodogiannis et al. (2008) | UTI | 14 CP (Bloodhound BH-114, Bloodhound Sensors Ltd., Leeds, UK) | implementation of an advanced NN |
| [ | Roine et al. (2014) | UTI | 6 MOS (ChemPro 100i, Environics Inc., Mikkeli, Finland) | LDA, LR, PCA |
| [ | Kodogiannis et al. (2005) | UTI | 32 CP (Cyranose E-320, Sensigent, Baldwin Park, CA, USA ) | NN, EM, SM |
| [ | Sabeel et al. (2013) | UTI | 32 CP (Cyranose E-320, Sensigent, Baldwin Park, CA, USA) | PCA |
| [ | Persaud et al. (2005) | UTI | CP | PCA |
| [ | Bernabei et al. (2007) | CD | 8 QCM | PCA, PLS-DA |
| [ | Weber et al. (2011) | CD | 12 MOS, 12 MOSFET, 1 capacitance-based humidity sensor and 1 IR-based CO2 sensor | PLS-DA |
| [ | Horstmann et al.(2015) | CD | MOS | PCA |
| [ | D’Amico et al. (2012) | CD | 8 QCM | PLS-DA |
| [ | Santonico et al. (2014) | CD | 8 QCM | PLS-DA |
| [ | Asimakopoulos et al. (2014) | CD | 8 QCM | PLS-DA |
| [ | Roine et al. (2014) | CD | 8 electrode strips and 1 MOS (ChemPro® 100, Environics Inc., Mikkeli, Finland) | LDA, LOOCV |
| [ | Westenbrink et al. (2014) | CD | 8 amperometric electro-chemical sensors (Alphasense Ltd., Great Notley, Essex, UK), 2 non-dispersive IR, optical devices (Clairair Ltd., Witham, UK) and 1 photo-ionisation detector (Mocon, Minneapolis, MN, USA). | LDA |
| [ | Satetha Siyang et al. (2012) | D | 8 commercial chemical gas sensors, based on change of resistance (TGS sensors) | PCA, CA |
| [ | Ping et al. (1997) | D | MOS | NN, fuzzy cluster pattern recognition |
| [ | Di Natale et al. (1999) | KD | QMB | PCA |
| [ | Arasaradnam et al. (2012) | BD | 6 MOS, 1 optical IR sensor, 1 pellistor, 6 electrochemical sensors | PCA, LDA |
| [ | Arasaradnam et al. (2013) | BD | 18 MOS (Fox 4000, AlphaMOS, Toulouse, France) | PCA |
| [ | Covington et al. (2013) | BD | 10 MOS | PCA, LDA |
| [ | Mohamed et al. (2013) | exposure to toxic agents | 10 MOS (PEN3, Airsense Analytics GmbH, Schwerin, Germany) | PCA |
Abbreviations: Genetic algorithms (GA), neural networks (NN), principal components analysis (PCA), discriminant function analysis and cross-validation (DFA-cv), Sliding Window-Minimum Variance matching adaptation of the Dynamic Time Warping algorithm (SW-MV, DTW), Multilayer perceptron (MLP), autoregressive exogenous type (ARX), Radial basis functions (RBFs), parametric Discriminant Function Analyses and cross validation (DFA-cv), linear discriminant analysis (LDA), logistic regression (LR), Expectation Maximization algorithm (EM), Split and Merge (SM), partial least squares-discriminant analysis (PLS-DA), leave-one-out cross-validation (LOOCV), cluster analysis (CA), bacteria cultures (BC), urinary tract infections(UTI), cancer diseases (CD), diabetes (D), kidney diseases (KD), bowel diseases (BD), metal oxide semiconductors (MOS), quartz microbalances (QMB or QCM), metal oxide semiconductor field effect transistor (MOSFET), conducting polymer (CP).
Scheme of the studies regarding the detection/identification of bacteria cultures.
| Ref. No. | Main Author | E-Nose Type | Bacterial Species | Culture Broths | Results |
|---|---|---|---|---|---|
| [ | Pavlou et al. | e-nose system with 14 CP | 36 blood agar plates (Merck, Anaerobic) | PCA→94% | |
| [ | Bruins et al. | Mono-nose | BD-BACTEC™—Plus-Anaerobic/F Medium with the addition of 0.1 mM FeCl3 | SW-MV, DTW→87% | |
| [ | Yates et al. | C320 | Blood used as the growth medium: various species of bacteria—including methicillin susceptible | Blood Urine | ARX→71% RBF→65% non linear ARX→80% BLOOD: ARX→94% RBF→71% Sammon maps + RBF→100% nonlinear ARX→72% |
| Urine from routine medical screening | |||||
| [ | Aathithan et al. | OMA | Agar | PCA→sensitivity 84%, specificity 88% |
Scheme of the studies regarding the detection/identification of UTI.
| Reference Number | Main Author | E-Nose Type | Bacterial Species | Culture Broths | Incu-Bation | Results |
|---|---|---|---|---|---|---|
| [ | Pavlou et al. | BH114-Blood-hound | Agar culture, brain heart infusion broth and cooked meat broth | 4 h 1/2 37 °C | GA-NN→prediction rate 100%, back propagation NN→prediction rate 98% | |
| [ | Kodogiannis et al. | BH114-Blood-hound | brain heart infusion broth and bovine serum | 5 h 37 °C | fuzzy integral methodology: (Advanced NN)→accuracy 100%, sensitivity 100%, specificity 100%, predictability 100% | |
| [ | Roine et al. | ChemPro 100i | cysteine lactose electrolyte deficient medium (CLED) Agar | no | LR used for the discrimination of sterile and infected samples→sensitivity 95%, specificity 97% LDA used for the classification of four different bacteria and sterile culture plate→sensitivity 95%, specificity of 96% | |
| [ | Kodogiannis et al. | BH114-Blood-hound | brain heart infusion broth and bovine serum | 5 h 37 °C | fuzzy integral fusion method (NN)→accuracy 100%,sensitivity 100%, specificity 100%, predictability, 100% adaptive-fuzzy-logic-system (AFLS) (NN)→prediction rate 92.86% | |
| [ | Sabeel et al. | Cyranose E-320 | - | - | - | - |
Scheme of the studies regarding cancer diseases.
| Reference Number | Main Author | E-Nose Type | Patho-Logies | Sample Preparation Method | Results | Sample |
|---|---|---|---|---|---|---|
| [ | Bernabei et al. | ENQBE | PC, BC | Urines collected in the morning, before any food intake. | PLS-DA→ discrimination between the patients and to the healthy controls 100%. PCA→not a complete discrimination between the two tumors, but a sort of gradual differentiation PCA→migration of post-surgery patients towards the healthy class | 131: 25 BC, 12 PC, 29 BPH, 33 various urological pathologies, 18 healthy control (19 patients measured twice, before and after the surgical treatment of cancer) |
| [ | Weber et al. | NST 3320 Lab Emission Analyser | BC | Storage at −80 °C, defrosted at room temperature (21 °C). | PLS-DA→healthy volunteers vs. bladder cancer patients: sensitivity 70%, specificity 70% PLS-DA→data of healthy controls suffer from other non-cancerous urological diseases: classification accuracy 65%, sensitivity 60%, specificity 67% | 89: 30 patients with BC, 59 healthy control |
| [ | Horstmann et al. | e-nose based on a MOS sensor | BC | - | PCA→sensitivity 75%, specificity 86% | 36: 15 BC 21 healthy control (with no pathologies or benign urological conditions like BPH and UTI) |
| [ | D’Amico | e-nose University of Rome “Tor Vergata” | PC | Samples collected in sterile urine boxes with a dedicated top to extract the headspace of urine for analysis. No more information are reported | PLS-DA→the results reported are only qualitative; data regarding classification accuracy, sensitivity and specificity of the adopted method are not discussed | 21 |
| [ | Santonico et al. | e-nose University of Rome “Tor Vergata” | PC | Measurements performed at room temperature. No more information are reported | PLS-DA→the results reported are only qualitative, no quantitative data are provided about the adopted method | 41: 27 healthy control, 14 PC |
| [ | Asimakopoulos et al. | e-nose University of Rome “Tor Vergata | PC | Measurement performed within 2 h from the collection | PLS-DA→sensitivity 71.4%, specificity 92.6% | 41 |
| [ | Roine et al. | ChemPro 100-eNose | PC | Sample defrosted and pipetted to a plate heated and maintained at 37 °C | LOOCV→sensitivity 78%, specificity 67% LDA→sensitivity 82%, specificity 88% | 74: 50 PC; 24 healthy control (15 BPH, 9 patients provided samples 3 months postoperatively) |
| [ | Westenbrink et al. | WOLF system | CRC | Storage at −80 °C, defrosted overnight at 5 °C. Samples heated to 40 °C for 5 min | LDA→sensitivity 78%, specificity 79% | 92: 39 CRC; 35 IBS; 18 healthy control |